Advanced searches left 3/3

Soft Tissue Sarcoma - DOAJ

Summarized by Plex Scholar
Last Updated: 20 June 2022

* If you want to update the article please login/register

Detection of Soft Tissue Sarcoma Recurrence: Feasibility of Ultrafast 3D Gradient-Echo Sequence in Addition to Conventional Contrast-Enhanced MRI to Provide Early-Phase Postcontrast Information

"This research seeks to determine the suitability of dual-phase postcontrast MRI sequences for the distinction of recurrent tumors from nonneoplastic lesions. " In this retrospective review, a total of 297 patients under postoperative surveillance for malignant STS were included in this retrospective research and divided into three subgroups, as follows: group A, recurrent tumors; group B, pseudomasses; and group C, postoperative inflammation. Results: All mean CNR and SIR values were significantly higher in group A during the early phase. However, the difference between early and delayed post-contrast MRI revealed a significantly smaller rise in group A than in the other groups when muscle was used as the reference tissue. A comparison of ROC curves revealed that dual-phase MRI had a much higher diagnostic success than traditional postcontrast MRI.

Source link: https://doi.org/10.5334/jbsr.2602


Complex Elucidation of Cells-of-Origin in Pediatric Soft Tissue Sarcoma: From Concepts to Real Life, Hide-and-Seek through Epigenetic and Transcriptional Reprogramming

"Soft tissue sarcoma" is a large group of mesenchymal malignant tumors with heterogeneous cellular morphology, proliferative index, genetic lesions, and, most importantly, clinical characteristics. Here, we discuss how cellular reprogramming mediated by driver genes in STS can dramatically change the molecular and morphological characteristics of a transformed cell and lead to the characterization of its cell-of-origin. This review questions the fact that the epigenetic environment in which a genetic modification arises must be considered as a primary predictor of STS tumor initiation and progression. ".

Source link: https://doi.org/10.3390/ijms23116310


The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era

After the failure of conventional chemotherapy, anLOTinib, a multitargeted tyrosine kinase inhibitor, had antitumor reactions on advanced soft tissue sarcoma after the failure of standard chemotherapy, according to the ALTER0203 clinical trial. We wanted to determine the true u2010world safety and health of anlotinib in patients with advanced STS, as well as prognostic factors and treatment patterns. Methods We retrospectively reviewed the results of patients with unresectable locally advanced or metastatic STS who received at least one dose of anlotinib from June 2018 to March 2021. For multivariate analysis, the Cox proportional hazards model was developed. Improved u2010free survival were largely linked to diet, Western Cooperative Oncology Group's success, and anlotinib treatment regimens, according to a substantial risk of progression. According to anlotinib-related toxicity, 31 patients, and 25 patients experienced dose reduction and treatment discontinuation, respectively, according to respective statistics. In a real world context, these results demonstrated the safety of anlotinib in patients with advanced STS in a real-u2025 world setting.

Source link: https://doi.org/10.1002/cam4.4613


PLOD Family: A Novel Biomarker for Prognosis and Personalized Treatment in Soft Tissue Sarcoma

"Despite multiple therapeutic strategies, the heterogenous group of soft tissue sarcomatas with more than 100 subtypes still has poor results. " PLOD1u20133 in STS was determined by using data from The Cancer Genome Atlas and Genotype-Tissue Expression databases in this research to determine the role of PLOD1u20133 in STS. The expression of PLOD genes in STS may be a novel biomarker for diagnosis and a more aggressive treatment in these patients.

Source link: https://doi.org/10.3390/genes13050787


Clinical Outcomes and Prognostic Factors in Soft Tissue Sarcoma Patients After Unplanned Excision

Patients with STS patients who underwent surgery at our hospital between 1999 and 2015 were enrolled either a UE group or a planned excision group, according to their findings and prognostic factors in STS patients with STS who underwent surgery. Conclusions: 110 patients were admitted to the PE group and 24 to the UE group of 134 patients undergoing STS surgery, and 24 were enrolled in the UE group to determine causes associated with prognosis after UE. Conclusion: Poorer DFS was attributed to older age and a larger primary tumor in patients undergoing PE, according to the UE group, and a prognosis similar to that in patients undergoing PE could be achieved by inserting new surgeries in patients initially undergoing UE. ".

Source link: https://doaj.org/article/21a212afc8c842ef89d17dd43d7e16f9


Local tumour response to neoadjuvant therapy with 2‐aminoethyl dihydrogen phosphate in dogs with soft tissue sarcoma

Background "Abstract Background In the case of soft tissue sarcoma, neoadjuvant therapy has been shown to delay the tumour prior to surgery in order to achieve improved local tumor control. Conclusions 2u2010AEH2F had no cytoreductive effects in tumoral regions relative to surrounding tissues throughout the course of therapy, according to an examination conducted in this research. ".

Source link: https://doi.org/10.1002/vms3.757

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions